Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 39 recruiting now full pipeline

Glaucoma: full-pipeline trial registry

39 of 94 indexed Glaucoma trials are currently recruiting.

Corpus placement: #143 of 28,707 conditions by registered trial count.

94 US clinical trials · 39 currently recruiting · #143 of 28,707 conditions by registered trial count

Glaucoma: 94 US clinical trials tracked, 39 recruiting.

Glaucoma is the subject of 94 registered US clinical trials on ClinicalTrials.gov, 39 of them currently open to new participants. 16 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is Stanford University, running 8 of these trials.

Enrollment posture brief

Registry condition glaucoma

OPEN 39 | RECR 41% | LATE 16 | EARLY 21 | RANK #143 | SPON 8

Nearest open-share peer: Post Traumatic Stress Disorder (42% recruiting · 265 trials)

Metastatic Malignant Solid N49.5%Substance Use Disorders45.7%Suicide44.1%Glaucoma (this)41%Fallopian Tube Cancer29%
Open-enrollment share among volume-matched conditions near Glaucoma

Glaucoma lists 39 open slots (41% of 94 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Glaucoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Glaucoma recruits in line with its size-band peers.

    39 of 94 indexed trials (41.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Glaucoma trials is spread across many organizations.

    Stanford University accounts for 8 of 94 trials (8.5%). 56 distinct sponsors appear on at least one study for this condition label.

  3. Typical Glaucoma enrolment sits around 92 participants.

    Median target enrolment is 92 among the 93 trials that report a genuine target (sentinel values excluded). 48 of those (51.6%) plan for fewer than 100 participants.

  4. Glaucoma research is mostly interventional.

    71 interventional and 23 observational studies make up this index (75.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 111Phase 210Phase 35Phase 411

Open and recent trials

94 total, page 1 of 2

RECRUITING NA 60,200 participants

Village-Integrated Eye Worker Trial II

University of California, San Francisco

NCT03752840

RECRUITING 5,000 participants

Novel Glaucoma Diagnostics

Wills Eye

NCT00286637

RECRUITING NA 2,000 participants

The Glaucoma and Retinopathy Screening Study

Massachusetts Eye and Ear Infirmary

NCT06882356

RECRUITING NA 1,800 participants

Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

University of Alabama at Birmingham

NCT06629649

RECRUITING NA 900 participants

Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2

University of Michigan

NCT06934577

RECRUITING Phase 2 610 participants

Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Glaukos Corporation

NCT07075718

RECRUITING NA 500 participants

Stem Cell Ophthalmology Treatment Study II

MD Stem Cells

NCT03011541

RECRUITING Phase 3 400 participants

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

SpyGlass Pharma

NCT07218783

RECRUITING Phase 3 400 participants

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

SpyGlass Pharma

NCT07218796

RECRUITING NA 300 participants

Comparison of Intraocular Pressure Measurement With the Novel TonoVera Device With Other Commonly Used Devices

State University of New York at Buffalo

NCT05523622

RECRUITING NA 245 participants

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

Glaukos Corporation

NCT06057051

RECRUITING NA 243 participants

A Trial of Hydrus Microstent Versus Goniotomy

Massachusetts Eye and Ear Infirmary

NCT06289491

RECRUITING Phase 2 228 participants

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Bausch & Lomb Incorporated

NCT07168902

RECRUITING NA 226 participants

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

University of Pennsylvania

NCT05924477

RECRUITING NA 200 participants

Automated Applanation Tonometry - Updated

Duke University

NCT07298356

RECRUITING 180 participants

Data Gathering for A10900

Optos

NCT07149740

RECRUITING 160 participants

Functional and Structural Imaging for Glaucoma

Oregon Health and Science University

NCT01957267

RECRUITING 150 participants

To Study Ocular Outflow Dynamics of the Eye Using Intraoperative Tonographic Biometry and Assess Its Predictive Value in Improving Postoperative Outcomes.

The New York Eye & Ear Infirmary

NCT07425496

RECRUITING NA 150 participants

Ocular Blood Flow Imaging for Glaucoma Assessment

University of Maryland, Baltimore

NCT05726058

RECRUITING Phase 3 142 participants

Pilocarpine Use After Kahook Goniotomy

Montefiore Medical Center

NCT03933631

RECRUITING 125 participants

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring

Smartlens

NCT06689696

RECRUITING Phase 4 90 participants

Retinal Blood Flow and Autoregulation

University of Maryland, Baltimore

NCT05344274

RECRUITING 75 participants

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

University of California, Los Angeles

NCT04354545

RECRUITING 60 participants

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

Brian Shafer

NCT07076303

RECRUITING NA 60 participants

Hyperbaric Oxygen Therapy for Optic Neuropathies

Stanford University

NCT06128720

RECRUITING NA 60 participants

Perimetric Testing With Virtual Reality

Envision Health Technologies

NCT06549010

RECRUITING 60 participants

Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy

University of Maryland, Baltimore

NCT06993597

RECRUITING NA 60 participants

Community Based Treatment for (ComBaT) Glaucoma

University of Michigan

NCT06124521

RECRUITING Phase 1 52 participants

Topical Insulin for Glaucoma

Stanford University

NCT05206877

RECRUITING NA 50 participants

Tolerability of an Anesthesia-free Tonometer Tip

Duke University

NCT06585423

RECRUITING NA 48 participants

Glaucoma Laser Assessment of Stability and Sustainability

Twin Cities Eye Consultants

NCT06963684

RECRUITING 46 participants

Eye Pressure Lowering Surgery

Oregon Health and Science University

NCT01931904

RECRUITING NA 45 participants

Electrical Stimulation for the Treatment of Glaucoma

Stanford University

NCT05626491

RECRUITING NA 40 participants

Electrical Stimulation for the Treatment of Optic Neuropathies

Stanford University

NCT05626426

RECRUITING NA 40 participants

The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients

Johns Hopkins University

NCT06971588

RECRUITING Phase 4 35 participants

Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

NCT07209410

RECRUITING 30 participants

Optimize Pediatric OCT Imaging

Duke University

NCT06139523

RECRUITING NA 30 participants

Electrical Stimulation for Vision Neuroenhancement in Glaucoma

Stanford University

NCT06685211

RECRUITING Phase 4 20 participants

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

University of Miami

NCT07217678

ACTIVE NOT RECRUITING NA 975 participants

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

iSTAR Medical

NCT05024695

ACTIVE NOT RECRUITING NA 749 participants

Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)

Columbia University

NCT04271709

ACTIVE NOT RECRUITING NA 358 participants

iStent Inject New Enrollment Post-Approval Study

Glaukos Corporation

NCT04624698

ACTIVE NOT RECRUITING 300 participants

A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases

Interstat

NCT07216677

ACTIVE NOT RECRUITING Phase 1 201 participants

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

SpyGlass Pharma

NCT06120842

ACTIVE NOT RECRUITING Phase 1 120 participants

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Laboratoires Thea

NCT05389267

ACTIVE NOT RECRUITING 116 participants

Anterior Segment Optical Coherence Tomography Microstent Positioning

University of Utah

NCT06666751

ACTIVE NOT RECRUITING 100 participants

Visual Field Analysis With Artificial Intelligence

Sight Intelligence Engineering Corporation

NCT06920290

ACTIVE NOT RECRUITING Phase 2 54 participants

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

Stanford University

NCT02862938

ACTIVE NOT RECRUITING Phase 2 30 participants

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

Stanford University

NCT04577300

ACTIVE NOT RECRUITING Early Phase 1 5 participants

A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery

Sanjay Asrani

NCT04918121

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 11
Phase 2 10
Phase 3 5
Phase 4 11

Named interventions

Most-linked intervention names on Glaucoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Latanoprost Drug
3 trials
Timolol Maleate Ophthalmic Solution, 0.5% Drug
3 trials
SpyGlass IOL Device
3 trials
Commercial IOL Device
2 trials
Bimatoprost Implant System Drug
2 trials
Repetitive, Transorbital Alternating Current Stimulation (rtACS) Device
2 trials
Latanoprost-PPDS Drug
1 trials

US sites by state

Facility locations filed on Glaucoma trials. A trial with sites in several states counts in each.

California 33 trials
New York 14 trials
Texas 10 trials
Pennsylvania 10 trials
North Carolina 9 trials
Maryland 9 trials
Massachusetts 8 trials
Florida 7 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Glaucoma page

94 registered trials, 39 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glaucoma condition card totals 94 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.